NLRP3 inflammasome in ischemic stroke: As possible therapeutic target

Int J Stroke. 2019 Aug;14(6):574-591. doi: 10.1177/1747493019841242. Epub 2019 Apr 2.

Abstract

Inflammation is a devastating pathophysiological process during stroke, a devastating disease that is the second most common cause of death worldwide. Activation of the NOD-like receptor protein (NLRP3)-infammasome has been proposed to mediate inflammatory responses during ischemic stroke. Briefly, NLRP3 inflammasome activates caspase-1, which cleaves both pro-IL-1 and pro-IL-18 into their active pro-inflammatory cytokines that are released into the extracellular environment. Several NLRP3 inflammasome inhibitors have been promoted, including small molecules, type I interferon, micro RNAs, nitric oxide, and nuclear factor erythroid-2 related factor 2 (Nrf2), some of which are potentially efficacious clinically. This review will describe the structure and cellular signaling pathways of the NLRP3 inflammasome during ischemic stroke, and current evidence for NLRP3 inflammasome inhibitors.

Keywords: Ischemic stroke; NLRP3 inflammasome; Nrf2; inflammation; interferon; micro RNA; nitric oxide; small molecule.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Humans
  • Inflammasomes / drug effects*
  • Inflammasomes / metabolism*
  • Inflammation / drug therapy*
  • Inflammation / metabolism*
  • NLR Family, Pyrin Domain-Containing 3 Protein / antagonists & inhibitors*
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism*

Substances

  • Anti-Inflammatory Agents
  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human